Primary aldosteronism: Are we missing the wood for the trees?

Hormone and Metabolic Research

Volumn 44, Issue 3, 2012, Pages 251-253

  Funder, J W ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

first line therapy; guidelines; public policy

Indexed keywords

EPLERENONE; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE;

CARDIOVASCULAR RISK; DRUG DOSE ESCALATION; DRUG SAFETY; ESSENTIAL HYPERTENSION; HUMAN; HYPERTENSION; LONG TERM CARE; LOW DRUG DOSE; NOTE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; THERAPY EFFECT;

ALDOSTERONE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC; RECEPTORS, MINERALOCORTICOID;

EID: 84858002799     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0031-1301281     Document Type: Note

References (9)

1. Auchus RJ. Primary aldosteronism and a Texas two-step. Rev Endocr Metab Disord 2001; 12: 37-42
2. Stowasser M, Sharman J, Leano R, Gordon RD, Ward G, Cowley D, Marwick TH. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab 2005; 90: 5070-5076 (Pubitemid 41262256)
3. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243-1248 (Pubitemid 40523144)
4. Takeda Y, Karashima S, Yoneda T. Primary aldosteronism, diagnosis and treatment in Japan. Rev Endoc Metab Disord 2011; 12: 21-25
5. Oliveri O, Ciacciarelli A, Signorelli D, Pizzozo F, Guarini P, Pavan C, Corgnati A, Falcone S, Corrocher R, Micchi A, Cressoni C, Biengio G. Aldosterone to renin ratio in a primary care setting: the Bussolengo Study. J Clin Endocrinol Metab 2004; 89: 4221-4226 (Pubitemid 39244414)
6. Levy D, Rocha R, Funder JW. Distinguishing the antihypertensive and electrolyte effects of eplerenone. J Clin Endocrinol Metab 2004; 89: 2736-2740 (Pubitemid 38766358)
7. Williams GH, Weinburger M, Lewin B, Krause S, Mukherjee R, Patni R, Beckerman B. Selective aldosterone blockade with eplerenone reduces albuminulla in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1: 940-951
8. Calhoun DA. Low dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension. J Clin Hypertens (Greenwich) 2007; 9: 19-24
9. Sechi LA, Colussi G, Di Fabio A, Catena C. Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment. Am J Hypertens 2010; 12: 1253-1260